Showing 24 results for Author: Roy Copping
Aug, 2026
Journal
Actinium-225 (t1/2 = 9.92 days) is an important radioisotope for targeted alpha therapy applications. The limited supply obtained through the decay of thorium-229 has motivated accelerator-based production routes, including irradiation of thorium targets. Irradiated targets can produce useful quantities of actinium-225, but the product requires final purification from chem…
Oct, 2025
ORNL Report
To reduce radioactive-gas emissions associated with processing thorium (Th) targets generated through the Tri-Lab process, the gas-trapping system was evaluated, modified, and reassessed to validate improved gas-trapping efficiency. Historical gamma-spectroscopy data from the Oak Ridge National Laboratory (ORNL) Building 4501 stack indicated the release of multiple antimon…
Dec, 2023
ORNL Report
Dec, 2023
Journal
Gadolinium vanadate nanoparticles (NPs) doped with europium, in concentrations between 5–40%, were synthesized via an aqueous route to prove their multimodal imaging functionalities and their performance as radionuclide carriers for targeted alpha therapy. Core–shell Gd0.8Eu0.2VO4 NPs were doped with the α-emitting actinium-225 to assess the in vitro retention of 225Ac and…
Nov, 2023
Journal
The development of targeted alpha therapy (TAT) as a viable cancer treatment requires innovative solutions to challenges associated with radionuclide retention to enhance local tumor cytotoxicity and to minimize off-target effects. Nanoparticles (NPs) with high encapsulation and high retention of radionuclides have shown potential in overcoming these issues. This article s…